Multicenter, Double-Blind, Randomized, 2-Arm, Parallel-Group, Equivalence Study Evaluating Efficacy and Safety Similarity of Mylan Adalimumab (MYL-1401A) Compared With Humira in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis

Trial Profile

Multicenter, Double-Blind, Randomized, 2-Arm, Parallel-Group, Equivalence Study Evaluating Efficacy and Safety Similarity of Mylan Adalimumab (MYL-1401A) Compared With Humira in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis

Completed
Phase of Trial: Phase III

Latest Information Update: 08 May 2017

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Sponsors Mylan
  • Most Recent Events

    • 02 May 2017 Status changed from active, no longer recruiting to completed.
    • 06 Apr 2017 This trial has been completed in Bulgaria and Hungary (End date:2017-03-06) as per European Clinical Trials Database record.
    • 01 Apr 2017 Trial status is completed in Estonia (end date: 2017-03-06) as per European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top